Old Web
English
Sign In
Acemap
>
authorDetail
>
Mary F. Michenzie
Mary F. Michenzie
ImmunoGen, Inc.
Folate Receptor Alpha
Ovarian cancer
Oncology
Maytansinoid
Pharmacodynamics
2
Papers
20
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Preliminary single agent activity of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial.
2015
Journal of Clinical Oncology
Kathleen N. Moore
Lainie P. Martin
Shelly Seward
Todd Michael Bauer
David M. O'Malley
Raymond P. Perez
Amit M. Oza
Woondong Jeong
Maurice Kirby
Yinghui Zhou
Mary F. Michenzie
Joseph Ponte
Rodrigo Ruiz-Soto
Michael J. Birrer
Show All
Source
Cite
Save
Citations (9)
Phase 1 study of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors.
2015
Journal of Clinical Oncology
Hossein Borghaei
David M. O'Malley
Shelly Seward
Todd Michael Bauer
Raymond P. Perez
Amit M. Oza
Woondong Jeong
Mary F. Michenzie
Maurice Kirby
Gurudatt Chandorkar
Rodrigo Ruiz-Soto
Michael J. Birrer
Kathleen N. Moore
Show All
Source
Cite
Save
Citations (11)
1